Company profile MREO
After 38 days of this quarter the interest is at 150.0. Based on that we can calculate that during remaining 53 days it will total up to 359.0. Mereo BioPharma expected interest is significantly higher compared to previous quarter (+165.9%) and same quarter last year (+97.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 188 | 305 62.2% QoQ | 113 -63.0% QoQ | 160 41.6% QoQ |
| 2020 | 47 -75.0% YoY -70.6% QoQ | 152 -50.2% YoY 223.4% QoQ | 222 96.5% YoY 46.1% QoQ | 214 33.8% YoY -3.6% QoQ |
| 2021 | 251 434.0% YoY 17.3% QoQ | 84 -44.7% YoY -66.5% QoQ | 251 13.1% YoY 198.8% QoQ | 203 -5.1% YoY -19.1% QoQ |
| 2022 | 179 -28.7% YoY -11.8% QoQ | 387 360.7% YoY 116.2% QoQ | 164 -34.7% YoY -57.6% QoQ | 225 10.8% YoY 37.2% QoQ |
| 2023 | 182 1.7% YoY -19.1% QoQ | 69 -82.2% YoY -62.1% QoQ | 257 56.7% YoY 272.5% QoQ | 135 -40.0% YoY -47.5% QoQ |
| 2024 | 150 -17.6% YoY 11.1% QoQ | - | - | - |
There is not enough data for Mereo BioPharma to provide correlation calculation
The average 5 years interest of Mereo BioPharma was 15.15 per week. The last year interest of Mereo BioPharma compared to the last 5 years has changed by 0.66%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -2.43%.
After 38 days of this quarter the interest is at 150.0. Based on that we can calculate that during remaining 53 days it will total up to 359.0. Mereo BioPharma expected interest is significantly higher compared to previous quarter (+165.9%) and same quarter last year (+97.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 188 | 305 62.2% QoQ | 113 -63.0% QoQ | 160 41.6% QoQ |
| 2020 | 47 -75.0% YoY -70.6% QoQ | 152 -50.2% YoY 223.4% QoQ | 222 96.5% YoY 46.1% QoQ | 214 33.8% YoY -3.6% QoQ |
| 2021 | 251 434.0% YoY 17.3% QoQ | 84 -44.7% YoY -66.5% QoQ | 251 13.1% YoY 198.8% QoQ | 203 -5.1% YoY -19.1% QoQ |
| 2022 | 179 -28.7% YoY -11.8% QoQ | 387 360.7% YoY 116.2% QoQ | 164 -34.7% YoY -57.6% QoQ | 225 10.8% YoY 37.2% QoQ |
| 2023 | 182 1.7% YoY -19.1% QoQ | 69 -82.2% YoY -62.1% QoQ | 257 56.7% YoY 272.5% QoQ | 135 -40.0% YoY -47.5% QoQ |
| 2024 | 150 -17.6% YoY 11.1% QoQ | - | - | - |
There is not enough data for Mereo BioPharma to provide correlation calculation
The average 5 years interest of Mereo BioPharma was 15.15 per week. The last year interest of Mereo BioPharma compared to the last 5 years has changed by 0.66%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -2.43%.
There is not enough data for etigilimab to provide analysis
There is not enough data for etigilimab to provide correlation calculation
There is not enough data for etigilimab to provide analysis
After 38 days of this quarter the interest is at 67.0. Based on that we can calculate that during remaining 53 days it will total up to 160.0. Navicixizumab expected interest is significantly higher compared to previous quarter (+119.2%) and same quarter last year (+inf%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 174 | 110 -36.8% QoQ | 173 57.3% QoQ | 106 -38.7% QoQ |
| 2020 | 59 -66.1% YoY -44.3% QoQ | 35 -68.2% YoY -40.7% QoQ | 126 -27.2% YoY 260.0% QoQ | 67 -36.8% YoY -46.8% QoQ |
| 2021 | 64 8.5% YoY -4.5% QoQ | 34 -2.9% YoY -46.9% QoQ | 82 -34.9% YoY 141.2% QoQ | 236 252.2% YoY 187.8% QoQ |
| 2022 | 14 -78.1% YoY -94.1% QoQ | 19 -44.1% YoY 35.7% QoQ | 180 119.5% YoY 847.4% QoQ | 40 -83.1% YoY -77.8% QoQ |
| 2023 | 0 -100.0% YoY -100.0% QoQ | 163 757.9% YoY inf% QoQ | 60 -66.7% YoY -63.2% QoQ | 73 82.5% YoY 21.7% QoQ |
| 2024 | 67 inf% YoY -8.2% QoQ | - | - | - |
There is not enough data for Navicixizumab to provide correlation calculation
The average 5 years interest of Navicixizumab was 7.24 per week. The last year interest of Navicixizumab compared to the last 5 years has changed by -3.59%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -35.55%.
There is not enough data for Acumapimod to provide analysis
There is not enough data for Acumapimod to provide correlation calculation
There is not enough data for Acumapimod to provide analysis
There is not enough data for Leflutrozole to provide analysis
There is not enough data for Leflutrozole to provide correlation calculation
There is not enough data for Leflutrozole to provide analysis
After 38 days of this quarter the interest is at 34.0. Based on that we can calculate that during remaining 53 days it will total up to 81.0. Setrusumab expected interest is significantly higher compared to previous quarter (+68.8%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 18 | 24 33.3% QoQ | 78 225.0% QoQ | 49 -37.2% QoQ |
| 2020 | 0 -100.0% YoY -100.0% QoQ | 233 870.8% YoY inf% QoQ | 103 32.1% YoY -55.8% QoQ | 116 136.7% YoY 12.6% QoQ |
| 2021 | 0 136.7% YoY -100.0% QoQ | 51 -78.1% YoY inf% QoQ | 112 8.7% YoY 119.6% QoQ | 90 -22.4% YoY -19.6% QoQ |
| 2022 | 49 inf% YoY -45.6% QoQ | 60 17.6% YoY 22.4% QoQ | 112 0.0% YoY 86.7% QoQ | 98 8.9% YoY -12.5% QoQ |
| 2023 | 120 144.9% YoY 22.4% QoQ | 107 78.3% YoY -10.8% QoQ | 66 -41.1% YoY -38.3% QoQ | 48 -51.0% YoY -27.3% QoQ |
| 2024 | 34 -71.7% YoY -29.2% QoQ | - | - | - |
There is not enough data for Setrusumab to provide correlation calculation
The average 5 years interest of Setrusumab was 6.03 per week. The last year interest of Setrusumab compared to the last 5 years has changed by 5.31%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 95.38%.
There is not enough data for Alvelestat to provide analysis
There is not enough data for Alvelestat to provide correlation calculation
There is not enough data for Alvelestat to provide analysis
After 38 days of this quarter the interest is at 117.0. Based on that we can calculate that during remaining 53 days it will total up to 280.0. osteogenesis imperfecta expected interest is significantly lower compared to previous quarter (-51.6%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 290 | 420 44.8% QoQ | 365 -13.1% QoQ | 423 15.9% QoQ |
| 2020 | 369 27.2% YoY -12.8% QoQ | 366 -12.9% YoY -0.8% QoQ | 331 -9.3% YoY -9.6% QoQ | 391 -7.6% YoY 18.1% QoQ |
| 2021 | 317 -14.1% YoY -18.9% QoQ | 286 -21.9% YoY -9.8% QoQ | 275 -16.9% YoY -3.8% QoQ | 309 -21.0% YoY 12.4% QoQ |
| 2022 | 365 15.1% YoY 18.1% QoQ | 376 31.5% YoY 3.0% QoQ | 332 20.7% YoY -11.7% QoQ | 342 10.7% YoY 3.0% QoQ |
| 2023 | 380 4.1% YoY 11.1% QoQ | 327 -13.0% YoY -13.9% QoQ | 344 3.6% YoY 5.2% QoQ | 578 69.0% YoY 68.0% QoQ |
| 2024 | 117 -69.2% YoY -79.8% QoQ | - | - | - |
There is not enough data for osteogenesis imperfecta to provide correlation calculation
The average 5 years interest of osteogenesis imperfecta was 28.09 per week. The last year interest of osteogenesis imperfecta compared to the last 5 years has changed by 9.61%. The interest for osteogenesis imperfecta is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -3.08%.
After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0. Alpha-1 anti-trypsin deficiency expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 184 inf% QoQ | 110 -40.2% QoQ | 35 -68.2% QoQ |
| 2020 | 50 inf% YoY 42.9% QoQ | 65 -64.7% YoY 30.0% QoQ | 18 -83.6% YoY -72.3% QoQ | 33 -5.7% YoY 83.3% QoQ |
| 2021 | 40 -20.0% YoY 21.2% QoQ | 44 -32.3% YoY 10.0% QoQ | 45 150.0% YoY 2.3% QoQ | 18 -45.5% YoY -60.0% QoQ |
| 2022 | 0 -100.0% YoY -100.0% QoQ | 41 -6.8% YoY inf% QoQ | 0 -100.0% YoY -100.0% QoQ | 75 316.7% YoY inf% QoQ |
| 2023 | 74 inf% YoY -1.3% QoQ | 46 12.2% YoY -37.8% QoQ | 122 inf% YoY 165.2% QoQ | 92 22.7% YoY -24.6% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
There is not enough data for Alpha-1 anti-trypsin deficiency to provide correlation calculation
The average 5 years interest of Alpha-1 anti-trypsin deficiency was 4.2 per week. The last year interest of Alpha-1 anti-trypsin deficiency compared to the last 5 years has changed by 41.9%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -9.7%.